Condition: Diabetic Macular Edema · Center-involved Diabetic Macular Edema · Sponsor: Alexandria University
The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement in patients with diabetic macular edema. The main question the study aims to answer is: Does dapagliflozin reduce the thickness of the macula when combined with the standard of care intravitreal anti-VEGF therapy more than the intravitreal anti-VEGF therapy alone?
This description comes directly from the study's public registry record.
Amira A. Nayel, Pharm.D, MSc · +201022715779 · gs-amira.nayel@alexu.edu.eg
Always discuss trial participation with your own doctor first.
| Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University | Alexandria, Alexandria Governorate, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06845163